Rapamycin Longevity News

New drug for Lp (a)

KarlT August 29, 2023, 12:19am #1

Muvalaplin as an Inhibitor of Lipoprotein(a) Formation

This phase 1 randomized clinical trial evaluates the safety, tolerability, pharmacokinetics, and exploratory pharmacodynamic biomarker effects of muvalaplin in humans.

6 Likes

Home
Categories
FAQ/Guidelines
Terms of Service
Privacy Policy

Powered by Discourse, best viewed with JavaScript enabled